Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Abstract

Muhammad Asad Faruqi,1 Malik M Khurram S Khan,1 David M Mannino1,2 1University of Kentucky College of Medicine, Lexington, KY, USA; 2COPD Foundation, Miami, FL, USACorrespondence: David M Mannino, Department of Medicine, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY, 40536, USA, Email [email protected]: Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor

Keywords

• chronic obstructive pulmonary disease
• therapy
• phospohodiesterase inhibitor